Nano medicine for pediatric rhabdomyosarcoma: drug and siRNA delivery by functionalized porous silicon nanoparticles
Nano medicine for pediatric rhabdomyosarcoma: drug and siRNA delivery by functionalized porous silicon nanoparticles
Embedded Files
Funding:
Literature
- Dominguez-Gil, S., Sala, R., Morel, V.J., Nguyen, C., Cheikh, K.E., Morère, A., Durand, J., Rössler, J., Bernasconi, M., Cunin, F., et al. (2024). Rhabdomyosarcoma targeting with tuned porous silicon nanoparticles.
- Gary‐Bobo, M., Mir, Y., Rouxel, C., Brevet, D., Basile, I., Maynadier, M., Vaillant, O., Mongin, O., Blanchard‐Desce, M., Morère, A., Garcia, M., Durand, J.‐O. and Raehm, L.
We aim to target and cure the very aggressive pediatric ARMS tumor with a highly specific nanomedicine approach, something that has never been achieved before.
In order to target MRD in disseminated ARMS tumor stages, we will use the recently developed multifunctional porous silicon nanoparticles (pSiNP) modified with targeting peptides to deliver chemotherapeutic agents, as well as siRNA against the PAX3-FOXO-1 fusion transcript.
In a very innovative approach, we will combine the delivery of chemotherapeutic drugs and siRNA in one NP
Page updated
Google Sites
Report abuse